Phosphodiesterase 4 catalyzes the hydrolysis of cyclic AMP and is a target for the development of anti-inflammatory agents. We have designed and synthesized a series of phenyl alkyl ketones as PDE4 inhibitors. Among them, 13 compounds were identified as having submicromolar IC50 values. The most potent compounds have IC50 values of in the mid- to low-nanomolar range. Compound 5v also showed preference for PDE4 with selectivity of >2000-fold over PDE7, PDE9, PDE2, and PDE5. Docking of 5v, 5zf, and 5za into the binding pocket of the PDE4 catalytic domain revealed a similar binding profile to PDE4 with rolipram except that the fluorine atoms of the difluoromethyl groups of 5v, 5za, and 5zf are within a reasonable range for hydrogen bond format...
AbstractSelective inhibitors against the 11 families of cyclic nucleotide phosphodiesterases (PDEs) ...
Cyclic nucleotide phosphodiesterases (PDEs) are a superfamily of enzymes controlling cellular concen...
Type 4 cAMP phosphodiesterase (PDE4) inhibitors show a broad spectrum of anti-inflammatory effects i...
Phosphodiesterase 4 catalyzes the hydrolysis of cyclic AMP and is a target for the development of an...
The phosphodiesterase 4 (PDE4) family of enzymes is a promising drug target for a variety of conditi...
AbstractPhosphodiesterases (PDEs) comprise a large family of enzymes that catalyze the hydrolysis of...
PDE4 inhibitors have been identified as therapeutic targets in a variety of conditions, particularly...
A new series of phosphodiesterase-9 (PDE9) inhibitors that contain a scaffold of 6-amino-pyrazolopyr...
The design, synthesis, and biological evaluation of new phosphodiesterase type 4 (PDE4) inhibitors, ...
PDE4 (phosphodiesterase-4)-selective inhibitors have attracted much attention as potential therapeut...
Subtype selectivity of phosphodiesterase 4 (PDE4) has been proposed to be the most salient feature f...
Subtype selectivity of phosphodiesterase 4 (PDE4) has been proposed to be the most salient feature f...
The phosphodiesterase 4 (PDE4) enzyme, which is responsible for hydrolyzing cAMP in immune cells and...
<p>cAMP, intracellular cyclic adenosine monophosphate, is a ubiquitous second messenger that plays a...
Type 4 phosphodiesterase (PDE4) inhibitors are emerging new treatment for a number of disorders incl...
AbstractSelective inhibitors against the 11 families of cyclic nucleotide phosphodiesterases (PDEs) ...
Cyclic nucleotide phosphodiesterases (PDEs) are a superfamily of enzymes controlling cellular concen...
Type 4 cAMP phosphodiesterase (PDE4) inhibitors show a broad spectrum of anti-inflammatory effects i...
Phosphodiesterase 4 catalyzes the hydrolysis of cyclic AMP and is a target for the development of an...
The phosphodiesterase 4 (PDE4) family of enzymes is a promising drug target for a variety of conditi...
AbstractPhosphodiesterases (PDEs) comprise a large family of enzymes that catalyze the hydrolysis of...
PDE4 inhibitors have been identified as therapeutic targets in a variety of conditions, particularly...
A new series of phosphodiesterase-9 (PDE9) inhibitors that contain a scaffold of 6-amino-pyrazolopyr...
The design, synthesis, and biological evaluation of new phosphodiesterase type 4 (PDE4) inhibitors, ...
PDE4 (phosphodiesterase-4)-selective inhibitors have attracted much attention as potential therapeut...
Subtype selectivity of phosphodiesterase 4 (PDE4) has been proposed to be the most salient feature f...
Subtype selectivity of phosphodiesterase 4 (PDE4) has been proposed to be the most salient feature f...
The phosphodiesterase 4 (PDE4) enzyme, which is responsible for hydrolyzing cAMP in immune cells and...
<p>cAMP, intracellular cyclic adenosine monophosphate, is a ubiquitous second messenger that plays a...
Type 4 phosphodiesterase (PDE4) inhibitors are emerging new treatment for a number of disorders incl...
AbstractSelective inhibitors against the 11 families of cyclic nucleotide phosphodiesterases (PDEs) ...
Cyclic nucleotide phosphodiesterases (PDEs) are a superfamily of enzymes controlling cellular concen...
Type 4 cAMP phosphodiesterase (PDE4) inhibitors show a broad spectrum of anti-inflammatory effects i...